NNOX vs HTFL vs CBLL Stock Comparison

Nano-X Imaging, Heartflow and Ceribell Prices as of Oct 27, 2026 Peers: Industry group
NNOX Nano-X Imaging Ltd.
$0.32 -50.0% 1M -92.1% 1Y
Market cap
$20.99M
P/E
–
Revenue (TTM)
$15.63M
Div. yield
–
Diagnostic Equipment Healthcare
1 win
HTFL Heartflow, Inc.
$57.82 +17.6% 1M +50.8% 1Y
Market cap
$5.12B
P/E
–
Revenue (TTM)
$202.91M
Div. yield
–
Diagnostic Equipment Healthcare
4 wins
CBLL Ceribell, Inc.
$27.22 +14.9% 1M +111.2% 1Y
Market cap
$1.04B
P/E
–
Revenue (TTM)
$101.96M
Div. yield
–
Diagnostic Equipment Healthcare
2 wins

Head to Head

7 decided of 12

Heartflow leads on 4 of the 12 questions below (Heartflow 4, Ceribell 2, Nano-X Imaging 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNNOXHTFLCBLLLeader
Larger companyMarket capitalisation $20.99M $5.12B $1.04B HTFL
Cheaper on earningsLower P/E, profitable companies only -0.2x -51.1x -15.7x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — — — –
Faster revenue growthRevenue growth, trailing twelve months +31.5% +42.5% +31.7% HTFL
More profitableNet margin, trailing twelve months -747.2% -49.4% -64.7% HTFL
Better return on capitalReturn on invested capital -116.9% — — –
Less leveragedLower net debt / EBITDA 0.3x — 1.6x NNOX
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -92.1% +50.8% +111.2% CBLL
Better 5-year returnAnnualised price return, 5 years -57.4%/yr — — –
Less volatileAnnualised volatility, 1 year 105.8% 76.7% 52.1% CBLL
Higher overall scoreMean of the five percentile scores vs peers 36/100 57/100 38/100 HTFL

Percentile Scorecard

NNOXHTFLCBLL

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNNOXHTFLCBLL
Valuation 54 #105 of 227 9 #207 of 227 22 #178 of 227
Growth 10 #198 of 219 78 #49 of 219 22 #172 of 219
Profitability 10 #185 of 206 49 #106 of 206 38 #129 of 206
Financial Health 71 #71 of 238 92 #20 of 238 81 #46 of 238
Shareholder Returns – – 30 #94 of 134
Overall 36 57 38
  • NNOX ranked among 247 companies in Medical Devices and Diagnostics
  • HTFL ranked among 247 companies in Medical Devices and Diagnostics
  • CBLL ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNNOXHTFLCBLLSPY
1 month -50.0%+17.6%+14.9% -0.2%
3 months -63.6%+125.9%+52.7% +3.9%
6 months -82.2%+89.3%+30.9% +8.2%
Year to date -88.6%+98.4%+24.1% +12.9%
1 year -92.1%+50.8%+111.2% +12.3%
3 years -93.6%—— +87.4%
3 years, per year -60.1%—— +23.3%
5 years -98.6%—— +67.9%
5 years, per year -57.4%—— +10.9%

Risk

MeasureNNOXHTFLCBLLSPY
Volatility, 1Y 105.8%76.7%52.1% 12.7%
Downside volatility, 1Y 116.3%77.5%49.5% 12.7%
Beta vs S&P 500, 1Y 1.361.901.21 1.00
Return / volatility, 1Y -0.870.662.13 0.97
Max drawdown, 5Y -98.8%-48.7%-63.9% -25.4%
From 52-week high -93.0%0.0%-1.7% -1.2%
52-week high $4.55$57.82$27.68 $779.14
52-week low $0.32$20.49$10.92 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNNOXHTFLCBLL
P/E now vs peer median -0.2xmedian 29.6x -49.9xmedian 29.6x -15.7xmedian 29.6x
P/S now vs peer median 1.4xmedian 2.9x 24.7xmedian 2.9x 10.2xmedian 2.9x
EV/EBITDA now vs peer median 0.1xmedian 17.4x —median 17.4x -13.6xmedian 17.4x
P/FCF now vs peer median -0.4xmedian 22.3x —median 22.3x -19.0xmedian 22.3x
P/B now vs peer median 0.3xmedian 2.3x 17.9xmedian 2.3x 8.1xmedian 2.3x
PEG now vs peer median -0.08median 1.04 —median 1.04 —median 1.04

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNNOXHTFLCBLL
Revenue $15.63M $202.91M $101.96M
Gross profit -$52.76M $160.45M $90.65M
Operating income -$119.69M -$64.46M -$69.97M
Net income -$116.81M -$100.19M -$66.00M
Free cash flow -$52.09M – -$54.72M
R&D $18.93M $77.26M $22.95M
EPS (diluted) $-1.80 $-1.16 $-1.74
Cash & equivalents $31.02M $34.36M $32.66M
Total debt $12.50M – $19.98M
Shares (diluted) 64.79M 86.40M 38.03M
Enterprise value -$158.68M $4.87B $439.26M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNNOXHTFLCBLL
P/E -0.2x -49.9x -15.7x
P/FCF -0.4x – -19.0x
P/Operating cash flow -0.5x – -19.3x
P/S 1.4x 24.7x 10.2x
P/B 0.3x 17.9x 8.1x
P/Tangible book 0.4x 17.9x 8.1x
EV/EBITDA 0.1x – -13.6x
EV/EBIT 0.0x -74.0x -13.3x
EV/Revenue -0.4x 23.5x 9.1x
EV/FCF 0.1x – -17.0x
EV/Operating cash flow 0.1x – -17.2x
PEG (3Y EPS CAGR) -0.08 – –

Growth

14 metrics
MetricNNOXHTFLCBLL
Revenue growth (1Y) 31.5% 42.5% 31.7%
Revenue CAGR (3Y) 17.7% – –
Gross profit growth (1Y) -340.0% 48.8% 33.4%
Gross profit CAGR (3Y) -101.8% – –
Operating income growth (1Y) -107.4% -9.5% -34.6%
Operating income CAGR (3Y) -5.0% – –
Net income growth (1Y) -109.9% -18.3% -33.6%
Net income CAGR (3Y) -4.9% – –
EPS growth (1Y) -90.0% 91.4% -27.5%
EPS CAGR (3Y) 2.3% – –
Operating cash flow growth (1Y) -21.9% – -44.3%
Operating cash flow CAGR (3Y) -2.7% – –
Free cash flow growth (1Y) -19.4% – -41.8%
Free cash flow CAGR (3Y) 1.3% – –

Profitability

14 metrics
MetricNNOXHTFLCBLL
Gross margin -337.5% 79.1% 88.9%
EBITDA margin -692.4% – -67.1%
Operating margin -765.6% -31.8% -68.6%
Pretax margin -758.5% -49.4% -64.7%
Net margin -747.2% -49.4% -64.7%
FCF margin -333.2% – -53.7%
Operating cash flow margin -298.7% – -53.0%
Return on equity -117.5% -34.5% -49.0%
Return on assets -98.6% -28.5% -38.3%
Return on invested capital -116.9% – –
Return on capital employed -114.2% -20.9% -45.1%
Asset turnover 0.1x 0.6x 0.6x
Cash conversion (OCF / net income) 0.4x – 0.8x
Stock comp / revenue 34.9% 9.6% 16.1%

Financial Health

11 metrics
MetricNNOXHTFLCBLL
Debt / assets 3.3% – 12.0%
Debt / equity 0.0x – 0.2x
Net debt / EBITDA 0.3x – 1.6x
Debt / FCF -0.1x – -0.4x
Liabilities / assets 20.5% 18.8% 22.9%
Equity / assets 79.5% 81.2% 77.1%
Interest coverage – – -38.6x
Current ratio 2.8x 5.1x 9.2x
Quick ratio 2.4x 6.6x 8.6x
Cash ratio 2.3x 5.6x 7.5x
Altman Z-score -11.07 42.47 14.47

Shareholder Returns

7 metrics
MetricNNOXHTFLCBLL
Dividend yield – – –
Net buyback yield – – -0.6%
Shareholder yield – – -0.6%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNNOXHTFLCBLL
EPS, next fiscal year $-1.31FY2026 $-0.43FY2026 $-1.86FY2026
Revenue, next fiscal year $18.64MFY2026 $261.38MFY2026 $118.32MFY2026
Revenue growth, next FY +43.2%FY2026 +48.5%FY2026 +32.9%FY2026
Revenue growth, the year after +59.6% +20.6% +21.1%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNNOXHTFLCBLL
Held by institutions 14.9% 100.0% 79.9%
Institutions holding 102 192 124
Change in shares held, QoQ -46.0% +133.0% +2.2%
Institutions buying 55 140 74
Institutions selling 28 38 36
Buyers to sellers 1.96 3.68 2.06

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NNOXHTFLCBLL
NNOX 1.00 0.19 0.14
HTFL 0.19 1.00 0.25
CBLL 0.14 0.25 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NNOX, HTFL and CBLL?

Heartflow (HTFL) is the largest by market capitalisation: Nano-X Imaging (NNOX) $20.99M, Heartflow (HTFL) $5.12B, Ceribell (CBLL) $1.04B.

Which company is growing faster?

Heartflow (HTFL) grew revenue fastest over the trailing twelve months: Nano-X Imaging (NNOX) +31.5%, Heartflow (HTFL) +42.5%, Ceribell (CBLL) +31.7%.

Which company is more profitable?

Heartflow (HTFL) has the highest net margin (Nano-X Imaging (NNOX) -747.2%, Heartflow (HTFL) -49.4%, Ceribell (CBLL) -64.7%).

Which stock has performed better?

Over the past year Ceribell (CBLL) returned the most: Nano-X Imaging (NNOX) -92.1%, Heartflow (HTFL) +50.8%, Ceribell (CBLL) +111.2%. Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Ceribell (CBLL) has been the steadiest (Nano-X Imaging (NNOX) 105.8%, Heartflow (HTFL) 76.7%, Ceribell (CBLL) 52.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, NNOX, HTFL and CBLL?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Heartflow (HTFL) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.